Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

by Zacks Equity Research

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Biogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BIIB vs. ILMN: Which Stock Is the Better Value Option?

Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment

by Zacks Equity Research

Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?

by Zacks Equity Research

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.

J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued in the second.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biohaven (BHVN) Begins Phase III Study on SMA Candidate

by Zacks Equity Research

Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.

Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's

by Zacks Equity Research

The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).

Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

by Zacks Equity Research

Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Sweta Killa headshot

5 Stocks in S&P 500 ETF That Gained Last Week

by Sweta Killa

The S&P 500 wrapped up its worst week since March 2020, tumbling 5.8%. Despite the massive decline, some of the stocks in SPY¿¿¿s portfolio have risen.

Kinjel Shah headshot

Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

by Kinjel Shah

Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.

Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints

by Zacks Equity Research

Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.

Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag

by Zacks Equity Research

The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.

Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug

by Zacks Equity Research

Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.

Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals

by Zacks Equity Research

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.

Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.

Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug

by Zacks Equity Research

Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.

Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension

by Zacks Equity Research

The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.

INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

by Zacks Equity Research

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.